Drugs / BIO-11006
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04183062 | Oct 2019 | Ewing sarcoma, osteosarcoma | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03472053 | Feb 2018 → Dec 2019 | non-small cell lung carcinoma | BioMarck Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00648245 | Jun 2008 → Jul 2010 | chronic obstructive pulmonary disease | BioMarck Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03202394 Comparator | Aug 2017 → Mar 2020 | adult acute respiratory distress syndrome | BioMarck Pharmaceuticals, Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIO 11006 | “This is a randomized, double blind, placebo controlled, parallel-group Phase IIa pilot study of aerosolized BIO 11006 in patients with sepsis-induced acute respiratory distress...” NCT03202394 ↗ |
| Known as | BIO-11006 Inhalation Solution | “The drug under evaluation in this study, BIO-11006 Inhalation Solution, is a new drug that may inhibit overproduction of mucus and may have important anti-inflammatory properties.” NCT00648245 ↗ |
| Action | Inhibit | “Myristoylated alanine-rich C-kinase substrate inhibitor” CHEMBL4297701 ↗1“may inhibit overproduction of mucus” NCT00648245 ↗ |
| Modality | Peptide | “This is a Phase 2, controlled study of BIO-11006 peptide given in addition to Gemcitabine and Docetaxel (GemTax) in the treatment of patients with advanced osteosarcoma or...” NCT04183062 ↗ |
| Route | Other | “by nebulizer” NCT00648245 ↗ |
| Target | MARCKS | “Myristoylated alanine-rich C-kinase substrate inhibitor” CHEMBL4297701 ↗ |